Olenovych O.A.

TUBULOINTERSTITIAL SYNDROME IN THE EARLY PERIOD OF ALLOXAN-INDUCED EXPERIMENTAL DIABETES

Department of Clinical Immunology, Allergology and Endocrinology
Bukovinian State Medical University

Adequate assessment of the functional renal state, especially in the case of early diagnosis of its disorders, requires an analysis not only of the glomerular apparatus of the kidney, but also of the condition of tubulointerstitial tissue (TIT) known to be involved in the pathological process in the kidneys much earlier than glomerular apparatus, and, consequently, the relatively preserved glomerular structure, however, does not ensure the normal functioning of the nephron. Among the known markers of TIT damage, one of the most important elements that reflects its function is sodium metabolism. Disorders of tubular sodium transport, its retention in the body and accumulation in renal structures lead to changes in local hemodynamics in the kidneys, hydrophilicity of renal tissue, disturbance of the water-osmotic balance and, consequently, to the defeat of TIT and progressive decline of renal function.

Considering the importance of timely diagnosis of tubulo-interstitial syndrome, its character, severity of TIT lesions for prediction of renal impairment progression intensity in clinical and experimental studies, the objective of this research was to clarify the peculiarities of tubulointerstitialsyndrome (TIS) in the early period of alloxan-induced experimental diabetes mellitus (EDM) known to be accompanied by the pathology of the interstitium, tubular-interstitial dysfunction.

The experiments were carried out on 18 white non-linear mature male rats. Experimental modeling of DM was performed by the intraperitoneal administration of *Alloxan monohydrate* to 8 animals in a diabetogenic dose of 160 mg/kg. On the 11th day after the induction of experimental diabetes mellitus in white non-linear male rats the kidneys of diabetic and control animals were removed, dissected to renal cortex, medulla and papilla for further measurement of tissue sodium content and calculation of papillary-cortical, papillary-medullar and medullary-cortical osmotic concentration sodium gradients.

The results of the investigation demonstrated a decrease of sodium concentration in all layers of the diabetic kidney, mainly in the renal papilla. The sodium content in the renal cortex of experimental animals was decreased by 54,0% ($P<0,001$), in the renal medulla – by 13,7% ($P<0,01$) and in the renal papilla its concentration was found to be 2,3-times less than control level ($P<0,001$). This significant decrease of sodium content in the renal tissue in experimental animals was accompanied by a reliable decline of osmotic concentration sodium papillary-medullar gradient (by 49,7%, $P<0,001$), a 2-fold increase of medullary-cortical gradient ($P<0,001$) and practically unchanged papillary-cortical gradient (by 2,5%, $P>0,3$) as compared to the control indices.

The detected changes of papillary-cortical, papillary-medullar and medullary-cortical osmotic concentration sodium gradients are indicative of the inhibition of proximal tubular sodium reabsorption and, despite regulatory control of the renal countercurrent multiplication system and intensification of sodium reabsorption at the level of the ascending Henle loop, excretion of urine with high osmolarity and significant sodium loss from the body.

Pankiv I.V.

EFFECT OF MYO-INOSITOL AND CHOLECALCIFEROL ON THYROID FUNCTION AND AUTOIMMUNITY IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM

Department of Clinical Immunology, Allergology and Endocrinology
Bukovinian State Medical University

In the absence of large randomized trials showing benefit from levothyroxine therapy, the rationale for treatment is based on the potential for decreasing the risk of adverse cardiovascular events and the possibility of preventing progression to overt hypothyroidism. Myo-inositol is the precursor of the synthesis of phosphoinositides, which are part of the phosphatidylinositol signal transduction pathway across the plasma membrane, via the second messenger 1,4,5-triphosphate